Profil
Harry S.
Palmin served as President, Chief Executive Officer, and Director at Novelos Therapeutics, Inc. from 2005 to 2013.
He also worked as Chief Financial Officer at Opexa Therapeutics, Inc. In 2022, he became the Chief Financial Officer at Acer Therapeutics, Inc. Mr. Palmin received his undergraduate degree from Brandeis University and his graduate degree from Brandeis International Business School.
Ehemalige bekannte Positionen von Harry Palmin
| Unternehmen | Position | Ende |
|---|---|---|
| ACER THERAPEUTICS INC. | Finanzdirektor/CFO | 17.11.2023 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Vorstandsvorsitzender | 01.10.2013 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Finanzdirektor/CFO | - |
Ausbildung von Harry Palmin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Brandeis University
Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and provides pharmaceutical drugs | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Health Technology |
Brandeis International Business School
Brandeis International Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for serious rare and life-threatening diseases | Health Technology |
















